Fragment 176-191 Peptide Overview
ADVERTISEMENT
Fragment 176-191 peptide, also known as HGH Fragment 176-191 or modified AOD-9604, has been proposed by researchers through laboratory experiments to possibly stimulate weight reduction and fat burn, in addition to helping to elevate IGF-1 levels in test subjects. This conclusion was reached by observing some potential in the peptide to help raise IGF-1 levels. As its name suggests, growth hormone, or HGH, is considered critical to development and growth in the first stages of life. In addition, HGH is an essential component that plays a central role in regulating various metabolic processes, including the induction of a hyperglycemic state and the upkeep of appropriate body weight. [i] Due to the prevalence of growth hormone (HGH) shortage and the many considered positive effects of the hormone, researchers have produced several synthetic peptides to compensate for deficits. These artificial peptides are condensed versions of the 191 amino acids in the growth hormone. [ii] One of these synthetic HGH peptides is called Fragment 176-191, and it has been the subject of extensive research within the context of weight regulation in animal test models.
Fragment 176-191 Peptide Overview
Studies suggest Fragment 176-191 is a synthetic peptide that may possibly perform the same functions as a Growth Hormone (HGH). It is made up of the amino acids 176-191. Fragment 176-191 seems to utilize the same mechanism as HGH to produce effects similar to those produced by HGH.
Research suggests the Fragment 176-191 peptide, also known as Frag 176-191, seems to activate the anterior pituitary gland. This, in turn, may hasten the pace at which the metabolism works and maybe mimic other functions that are similar to those of HGH. Because of this, researchers speculate the peptide might be responsible for increased growth and development. In addition, the recombinant growth hormone known as somatotropin was produced to connect with the growth hormone receptors situated in various sites, the liver being the most prominent of these sites. As soon as the rhGH connects with the receptors, it seems to trigger the creation of insulin-like growth factors known as IGF-1 and IGF-2. [iii] Scientists hypothesize that peptides may promote glucose homeostasis and high metabolism of carbohydrates and fats due to elevated IGF factors. The following is a list of the primary areas of focus that researchers have hypothesized about the peptide: [iii]
- Possible acceleration in the pace of cell growth
- The possible quickening of the metabolism
- A possible decrease in insulin sensitivity
- Possible tissue repair properties
Fragment 176-191 Peptide Research
Fragment 176-191 Peptide and Growth Hormone Deficiency
Growth hormone deficiency (GHD) symptoms are considered to often include:
- Stunted growth over a lifetime.
- Stagnancy in weight.
- Accelerated bone aging.
Throughout the last few years, five studies have been carried out in which GHD test subjects were given the synthetic peptide in various quantities to investigate its effect and potential. Each research included certain requirements, such as being smaller in height/length than average control measures, meeting certain parameters for bone age, and demonstrating rapid development. Only the models that met these requirements were observed over the course of the research. The studies’ findings suggested that presenting the peptide to test models led to the possibility of increased height and length. [iv]
Fragment 176-191 and Glycogen Metabolism
Within the scope of one investigation [v], normal functioning rats were given a variety of synthetic HGH peptides, one of which being Fragment 176-191, to evaluate the compound's possible impact on glycogen metabolism. It was suggested the peptide might generate a modest increase in blood glucose and lactate levels, along with a possible minor decrease in the ratio of glycogen synthase in muscle, adipose tissues, and the liver. It was hypothesized that this result was brought about by the peptide's apparent primary potential: to convert the enzymes from their active state to inactive one. This function was hypothesized even though the synthase levels seemed to be unaffected.
Fragment 176-191 and Diabetic Ulcerations
For this clinical investigation, ten subjects with type I and type II Diabetes previously diagnosed with diabetic foot ulcers (DFU) were observed as test models. The subjects were randomly assigned to one of two groups: the control group received alginate dressing, while the experimental group received both the alginate dressing and the rhGH Fragment 176-191 peptide. The control group served as the baseline for comparison with the experimental group. The researchers were divided on their opinions on the results of this study. The exact mechanism of how the peptide may affect DFU is not completely understood. Researchers hypothesize three distinct processes at play here: first, the stimulation of cell proliferation and cell development; second, immunomodulatory capabilities; and third, angiogenesis. The results of the investigation were inconclusive.
Fragment 176-191 for sale online is restricted to usage in research and educational institutes, and is currently under further scientific investigtion. Biotech Peptides is a reputable resource for research peptides, see their full product line here. It should be noted that sales are restricted to verified professionals and active scientists only. This article's information is meant only for educational purposes, and is not intended to provide medical or research advice.
References
[i] Brinkman JE, Tariq MA, Leavitt L, et al. Physiology, Growth Hormone. [Updated 2021 May 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. https://www.ncbi.nlm.nih.gov/books/NBK482141/
[ii] National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 16131230, Somatotropin (176-191). Retrieved June 21, 2021. https://pubchem.ncbi.nlm.nih.gov/compound/Somatotropin-_176-191
[iii] Clinical info drug database. https://clinicalinfo.hiv.gov/en/drugs/somatropin/patient
[iv] Reh, C. S., & Geffner, M. E. (2010). Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review. Clinical pharmacology : advances and applications, 2, 111–122. https://pubmed.ncbi.nlm.nih.gov/22291494/
[v] G.Y.W. Ma et al, The mechanism of the hyperglycaemic action of synthetic peptides related to the C-terminal sequence of human growth hormone, Biochimica et Biophysica Acta (BBA) – General Subjects, Volume 716, Issue 3, 1982, Pages 400-409, ISSN 0304-4165, https://doi.org/10.1016/0304-4165(82)90033-2
Disclaimer: The views and opinions expressed in this sponsored article are those of the sponsor/author/agency and do not represent the stand and views of Mid-Day Group.Mid-Day Group disclaims any and all liability to any party, company or product for any direct, indirect, implied, punitive, special, incidental or consequential damages arising directly or indirectly from the use of this content.
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
